Nurix Therapeutics Income Statement (2019-2026) | NRIX

Income Statement Aug2019 Nov2019 Feb2020 May2020 Aug2020 Nov2020 Feb2021 May2021 Aug2021 Nov2021 Feb2022 May2022 Aug2022 Nov2022 Feb2023 May2023 Aug2023 Nov2023 Feb2024 May2024 Aug2024 Nov2024 Feb2025 May2025 Aug2025 Nov2025 Feb2026 May2026
Revenue & cost
Revenue (Quarter)
10.25M7.40M9.62M11.43M10.79M6.78M12.69M30.68M18.47M15.16M16.59M12.09M12.59M13.28M18.45M44.06M7.89M13.58M6.25M9.04M
Operating items
Research & Development (Quarter)
30.91M36.53M43.14M47.49M47.76M46.11M45.82M45.76M47.86M49.71M50.01M48.92M55.48M67.22M69.66M78.10M86.12M83.02M84.14M87.65M
Selling, General & Administrative (Quarter)
8.34M8.82M9.23M9.65M9.75M9.37M9.82M11.68M10.62M10.78M11.80M11.71M11.72M10.72M11.65M14.28M13.16M13.65M14.61M15.59M
Operating Expenses (Quarter)
39.25M45.35M52.37M57.15M57.51M55.47M55.64M57.44M58.48M60.49M61.80M60.63M67.20M77.94M81.32M92.38M99.28M96.67M98.75M103.25M
Operating Income (Quarter)
-29.00M-37.95M-42.74M-45.72M-46.72M-48.69M-42.95M-26.77M-40.01M-45.33M-45.22M-48.54M-54.61M-64.66M-62.86M-48.32M-91.39M-83.09M-92.50M-94.20M
EBIT (Quarter)
-29.00M-37.95M-42.74M-45.72M-46.72M-48.69M-42.95M-26.77M-40.01M-45.33M-45.22M-48.54M-54.61M-64.66M-62.86M-48.32M-91.39M-83.09M-92.50M-94.20M
Non-operating items
Interest & Investment Income (Quarter)
0.04M0.29M0.21M0.31M1.01M1.97M2.22M2.49M3.03M3.38M3.79M4.08M5.74M6.12M6.51M5.62M4.96M4.87M5.32M4.40M
Net income details
EBT (Quarter)
-28.96M-37.66M-42.53M-45.40M-45.71M-46.72M-40.73M-24.28M-36.98M-41.96M-41.43M-44.46M-48.87M-58.54M-56.35M-42.70M-86.42M-78.22M-87.95M-89.81M
Tax Provisions (Quarter)
-0.10M0.03M0.09M0.09M0.08M0.01M0.76M-0.27M
Profit After Tax (Quarter)
-28.84M-37.70M-42.53M-45.40M-45.71M-46.72M-40.73M-24.28M-36.98M-41.96M-41.52M-44.55M-48.96M-58.55M-56.35M-43.46M-86.42M-78.22M-87.17M-89.53M
Income from Non-Controlling Interests (Quarter)
0.30M0.21M0.08M-0.25M-0.05M
Income from Continuing Operations (Quarter)
-28.86M-37.69M-42.53M-45.40M-45.71M-46.72M-40.73M-24.28M-36.98M-41.96M-41.52M-44.55M-48.96M-58.55M-56.35M-43.46M-86.42M-78.22M-87.95M-89.53M
Consolidated Net Income (Quarter)
-28.86M-37.69M-42.53M-45.40M-45.71M-46.72M-40.73M-24.28M-36.98M-41.96M-41.52M-44.55M-48.96M-58.55M-56.35M-43.46M-86.42M-78.22M-87.95M-89.53M
Income towards Parent Company (Quarter)
-28.86M-37.69M-42.53M-45.40M-45.71M-46.72M-40.73M-24.28M-36.98M-41.96M-41.52M-44.55M-48.96M-58.55M-56.35M-43.46M-86.42M-78.22M-87.95M-89.53M
Net Income towards Common Stockholders (Quarter)
-28.86M-37.69M-42.53M-45.40M-45.71M-46.72M-40.73M-24.28M-36.98M-41.96M-41.52M-44.55M-48.96M-58.55M-56.35M-43.46M-86.42M-78.22M-87.95M-89.53M
Additional items
EPS (Basic) (Quarter)
-0.65-0.88-0.95-1.01-0.90-0.96-0.75-0.45-0.68-0.77-0.76-0.71-0.67-0.87-0.67-0.52-1.03-0.90-0.80-0.81
EPS (Diluted) (Quarter)
-0.65-0.88-0.95-1.01-0.90-0.96-0.75-0.45-0.68-0.77-0.76-0.71-0.67-0.87-0.67-0.52-1.03-0.90-0.80-0.81
Shares Outstanding (Quarter)
44.37M42.90M44.69M44.90M50.87M48.61M54.03M54.26M54.39M54.34M54.90M62.38M72.78M67.12M83.56M83.88M84.16M86.67M110.07M111.08M
Shares Outstanding (Diluted) (Quarter)
44.37M42.90M44.69M44.90M50.87M48.61M54.03M54.26M54.39M54.34M54.90M62.38M72.78M67.12M83.56M83.88M84.16M86.67M110.07M111.08M
EBITDA (Quarter)
-29.00M-37.95M-42.74M-45.72M-46.72M-48.69M-42.95M-26.77M-40.01M-45.33M-45.22M-48.54M-54.61M-64.66M-62.86M-48.32M-91.39M-83.09M-92.50M-94.20M
Interest Expenses (Quarter)
85.38M1.24M24.25M49.46M48.08M1.38M1.39M1.12M2.79M1.92M0.40M0.10M2.14M2.15M0.50M0.10M1.71M0.78M0.40M
Tax Rate (Quarter)
0.35%-0.08%-0.22%-0.20%-0.17%-0.01%-1.78%0.30%